Skip to main content

Table 2 Crude and adjusted regression analysis of diagnostic time up to 3 months and independent variables in patients with rheumatoid arthritis in Blumenau, Santa Catarina, Brazil, 2014

From: Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil

Variables Crude analysis Adjusted analysis
(PRc) CI 95% p (PRa) CI 95% p
Sex (n = 296) 0,146    0,154**
 Male 0,84 (0,6-1,0)   0,85 (0,6-1,0)  
 Female 1    1   
Age in years (n = 287) 0,200    0,267**
 20–39 1    1   
 40–59 0,83 (0,6-1,0)   0,84 (0,6-1,0)  
  ≥ 60 0,80 (0,6-1,0)   0,81 (0,6-1,0)  
Education in completed years (n = 284) 0,459*    0,314**
 0–4 0,93 (0,7-1,1)   0,90 (0,7-1,0)  
 5–8 1,08 (0,9-1,2)   1,07 (0,9-1,2)  
  > 9 1    1   
Current monthly personal income in minimum wages (n = 248) 0,801*    0,622**
 Third tertile (higher) 1    1   
 Second tertile 1,01 (0,8-1,2)   1,01 (0,8-1,2)  
 First tertile (lower) 0,97 (0,8-1,1)   0,95 (0,7-1,1)  
Body mass index (Kg/m2) (n = 285) 0,010    0,031
  ≤ 24,9 1    1   
 25–29,9 1,18 (0,9-1,4)   1,16 (0,9-1,4)  
  ≥ 30 1,26 (1,0-1,5)   1,23 (1,0-1,5)  
Type of servicee in the last 12 months (n = 269) 0,177    0,623**
 Public healthcare system 0,87 (0,7-1,0)   0,95 (0,7-1,1)  
 Supplementary healthcare system 0,95 (0,8-1,1)   0,96 (0,8-1,1)  
 Fee-for-service care 1    1   
Total number of consultations with a rheumatologist in the last 12 months (n = 281) 0,165    0,163**
 0–1 0,86 (0,6-1,1)   0,85 (0,6-1,0)  
 2–3 1    1   
  ≥ 4 0,89 (0,7-1,0)   0,89 (0,7-1,0)  
Disease time in months (n = 235) 0,247*    0,605**
 0–24 1    1   
  > 24 1,16 (0,8-1,5)   1,07 (0,8-1,3)  
Use of csDMARD (n = 296) 0,383*    0,283**
 Yes 1    1   
 No 1,06 (0,9-1,2)   1,12 (0,9-1,3)  
Use of TNFi (ADA + ETA+IFX) (n = 288) 0,960*    0,277**
 Yes 0,99 (0,8-1,1)   0,88 (0,7-1,0)  
 No 1    1   
HAQ (n = 165) 0,901*    0,587**
 0–1 (mild) 1    1   
 1,1–2 (moderate) 0,89 (0,7-1,1)   0,86 (0,6-1,1)  
 2,1–3 (severe) 1,01 (0,8-1,2)   0,92 (0,6-1,3)  
Presence of radiological changes (erosions) in hands (n = 237) 0,814*    0,306**
 No 1    1   
 Yes 0,98 (0,8-1,1)   1,13 (0,8-1,4)  
Current professional situation (237) 0,324*    0,637**
 Working 1    1   
 Health insurance 0,99 (0,7-1,2)   0,99 (0,7 – 1,4)  
 Disability retirement 0,94 (0,7-1,1)   0,89 (0,6 – 1,1)  
 Retirement for time of service 0,91 (0,7-1,1)   0,95 (0,7 – 1,2)  
  1. csDMARD conventional synthetic disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitors, ADA adalimumab, ETA etanercept, IFX infliximab, HAQ health assessment questionnaire, PRc crude prevalence ratio, PRa adjusted prevalence ratio; CI 95%: confidence interval of 95%
  2. * Value of p > 0,20 excluded from the adjusted analysis. ** Value of p > 0,05 excluded of final model
Back to article page

Advances in Rheumatology

ISSN: 2523-3106